• webmaster@caristem.org

Inhalation drug delivery is mainly used for the treatment of lung conditions such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, bacterial infection as well as lung tumours through topical action on the lungs (Kleinstreuer, 2011). The fact that inhaled drugs can reach the blood system can be a drawback for lung therapy as it increases the risk of side effects. This is an issue for the delivery of certain inhaled active pharmaceutical ingredients (APIs) such as corticosteroids which increase the risk of osteoporosis in particular for postmenopausal women (Lipworth, 1999).